Trevive Use In Pregnancy & Lactation

Women of child bearing potential: Women of childbearing potential must be advised to use effective contraception during treatment.
Pregnancy: There are limited data on the use of imatinib in pregnant women. Imatinib Tablets should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.
Breast-feeding: There is limited information on imatinib distribution on human milk. Both imatinib and its active metabolite were observed to be distributed into human milk. Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking imatinib should not breast-feed.
Fertility: Studies on patients receiving Imatinib Tablets and its effect on fertility and gametogenesis have not been performed. Patients concerned about their fertility on Imatinib Tablets treatment should consult with their physician.